{
    "root": "31684ce0-6e7d-a1d7-e063-6394a90a39db",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rosuvastatin",
    "value": "20250328",
    "ingredients": [
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "ROSUVASTATIN",
            "code": "413KH5ZJ73"
        }
    ],
    "indications": "rosuvastatin tablets indicated : reduce risk major cardiovascular ( cv ) events ( cv death , nonfatal myocardial infarction , nonfatal stroke , arterial revascularization procedure ) adults without established coronary heart disease increased risk cv disease based age , high-sensitivity c-reactive protein ( hscrp ) \u22652 mg/l , least one additional cv risk factor . adjunct diet : reduce low-density lipoprotein cholesterol ( ldl-c ) adults primary hyperlipidemia . reduce ldl-c slow progression atherosclerosis adults . reduce ldl-c adults pediatric patients aged 8 years older heterozygous familial hypercholesterolemia ( hefh ) . adjunct ldl-c-lowering therapies , alone treatments unavailable , reduce ldl-c adults pediatric patients aged 7 years older homozygous familial hypercholesterolemia ( hofh ) . adjunct diet treatment adults : primary dysbetalipoproteinemia . hypertriglyceridemia .",
    "contraindications": "take orally without food , time day . ( 2.1 ) assess ldl-c clinically appropriate , early 4 weeks initiating rosuvastatin tablets , adjust necessary . ( 2.1 ) adults : recommended range 5 mg 40 mg daily . ( 2.1 ) pediatric patients hefh : recommended range 5 mg 10 mg daily patients aged 8 less 10 years age , 5 mg 20 mg daily patients aged 10 years older . ( 2.2 ) pediatric patients hofh : recommended 20 mg daily patients aged 7 years older . ( 2.2 ) asian patients : initiate 5 mg daily . consider risks benefits treatment adequately controlled doses 20 mg daily . ( 2.4 ) patients severe renal impairment ( hemodialysis ) : initiate 5 mg daily ; exceed 10 mg daily . ( 2.5 ) full prescribing information rosuvastatin tablets modifications due . ( 2.6 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "rosuvastatin tablets contraindicated following conditions : acute liver failure decompensated cirrhosis [ ( 5.3 ) ] . hypersensitivity rosuvastatin excipients rosuvastatin tablets . hypersensitivity including rash , pruritus , urticaria , angioedema reported rosuvastatin tablets [ ( 6.1 ) ] .",
    "indications_original": "Rosuvastatin tablets are indicated:\n                  \n                     \n                        To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) \u22652 mg/L, and at least one additional CV risk factor.\n                     \n                     As an adjunct to diet to:\n  \n   \n                           Reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.\n                           Reduce LDL-C and slow the progression of atherosclerosis in adults.\n                           Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                        \n                     \n                  \n                  \n                     As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).\n                     As an adjunct to diet for the treatment of adults with:\n  \n   \n                           Primary dysbetalipoproteinemia.\n                           Hypertriglyceridemia.",
    "contraindications_original": "Take orally with or without food, at any time of day. ( 2.1 ) Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin tablets, and adjust dosage if necessary. ( 2.1 ) Adults: Recommended dosage range is 5 mg to 40 mg once daily. ( 2.1 ) Pediatric Patients with HeFH: Recommended dosage range is 5 mg to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 mg to 20 mg once daily for patients aged 10 years and older. ( 2.2 ) Pediatric Patients with HoFH: Recommended dosage is 20 mg once daily for patients aged 7 years and older. ( 2.2 ) Asian Patients: Initiate at 5 mg once daily. Consider risks and benefits of treatment if not adequately controlled at doses up to 20 mg once daily. ( 2.4 ) Patients with Severe Renal Impairment (not on hemodialysis): Initiate at 5 mg once daily; do not exceed 10 mg once daily. ( 2.5 ) See full prescribing information for rosuvastatin tablets dosage and administration modifications due to drug interactions. ( 2.6 )",
    "adverseReactions_original": "Rosuvastatin tablets are contraindicated in the following conditions:\n                  \n                     Acute liver failure or decompensated cirrhosis\n  \n   [see\n   \n    Warnings and Precautions (5.3)]\n  \n   .\n \n  \n                     Hypersensitivity to rosuvastatin or any excipients in rosuvastatin tablets. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin tablets\n  \n   [see\n   \n    Adverse Reactions (6.1)]\n  \n   ."
}